C1:SG + SHR3162

There is no publicly available information on a drug or combination named "C1:SG + SHR3162" in major drug databases or clinical trial registries. The name appears to be a code for an experimental combination, possibly involving a C1 esterase inhibitor (such as those used for hereditary angioedema) and another investigational agent (SHR3162). However, there is no evidence that this specific combination exists as a marketed product or has been described in published literature. If "C1:SG" refers to a specific formulation of C1 esterase inhibitor and "SHR3162" is an investigational compound, the mechanism of action would depend on the individual components. C1 esterase inhibitors regulate complement and contact system activation by inhibiting plasma kallikrein and factor XIIa, thereby preventing bradykinin production[4]. The mechanism of SHR3162 is not specified in available sources.